Aripiprazole Dosing for Tic Disorders
For children ≥6 years and adolescents with tic disorders, start aripiprazole at 2 mg/day and titrate to a target dose of 5-10 mg/day (maximum 20 mg/day for patients <50 kg). For adults, the typical effective dose range is 5-20 mg/day, though doses up to 45 mg/day have been used in treatment-refractory cases 1, 2, 3.
Pediatric Dosing (Children ≥6 years and Adolescents)
Titration schedule:
- Increase to 5 mg after 2 days
- Target dose of 10 mg after 2 additional days
- Subsequent increases in 5 mg increments if needed 1
Weight-based targets:
- Patients <50 kg: Target doses of 2,5, or 10 mg/day (maximum 20 mg/day) 2
- Patients ≥50 kg: Target doses of 5,10,15, or 20 mg/day 2
The most robust pediatric evidence comes from a 2024 randomized, double-blind, placebo-controlled trial (n=121) using aripiprazole oral solution, which demonstrated significant improvement in tic severity with a response rate of 86.4% versus 56.6% for placebo 2. This study used flexible dosing from 2-20 mg/day based on weight, with excellent tolerability—all adverse events were mild to moderate, and no serious adverse events occurred.
Adult Dosing
Effective dose range: 5-20 mg/day (mean effective dose approximately 17 mg/day) 3
Maximum dose: Up to 45 mg/day in treatment-refractory cases, though optimal dosing is highly individualized 3
The largest adult case series (n=100) found that 82% of patients achieved considerable tic reduction with doses ranging from 5-45 mg/day (mean 17 mg), with beneficial effects sustained beyond 12 months in 48 patients 3. However, 31% discontinued due to inefficacy or adverse effects (drowsiness, agitation, weight gain, sleep disturbances), highlighting the need for individualized dosing.
Clinical Context and Monitoring
Aripiprazole is now considered first-line pharmacological treatment for tic disorders based on its favorable efficacy-to-side-effect profile compared to traditional dopamine antagonists like haloperidol and pimozide 5. The 2022 European clinical guidelines for Tourette syndrome explicitly recommend aripiprazole as the preferred dopamine-blocking agent due to fewer extrapyramidal side effects 5.
Key monitoring parameters:
- Tic severity (Yale Global Tic Severity Scale)
- Weight and metabolic parameters
- Extrapyramidal symptoms
- Sedation/drowsiness
- Sleep disturbances
Important caveats:
- Behavioral therapy should be considered first-line when available and feasible, with pharmacotherapy reserved for cases where behavioral approaches are ineffective, unavailable, or insufficient 5
- Response typically occurs within 2 weeks, with continued improvement over 8-12 weeks 2, 6, 4
- The dropout rate of approximately 30% in clinical practice necessitates close monitoring during initial titration 3
- Dose adjustments are required for CYP2D6 poor metabolizers and patients on CYP3A4/CYP2D6 inhibitors or inducers 7
Preliminary therapeutic serum concentration ranges from recent TDM data suggest 60-140 ng/mL for behavioral/tic disorders in youth, though this requires further validation 8.